Showing 601-610 of 628 results for "".
- Kylie Jenner Sells Majority Stake in Beauty Business to Cotyhttps://modernaesthetics.com/news/kylie-jenner-sells-majority-stake-in-beauty-business-to-coty/2472846/Kylie Jenner sold a $600M majority stake in Kylie Cosmetics and Kylie Skin to Coty Inc. Under the terms of the agreement, Coty will acquire a 51 percent ownership in the partnership for $600M. The acquisition is expected to close in the third quarter of fiscal year 2020. Coty's
- Cutera Introduces truSculpt flex for Toning Abs, Butts and Thighshttps://modernaesthetics.com/news/cutera-introduces-trusculpt-flex-for-toning-abs-butts-and-thighs/2471887/Cutera is launching the new truSculpt flex, muscle sculpting platform in the United States, and commercial shipments are slated to begin immediately. truSculpt flex is FDA-cleared for the indications of the improvement of abdominal tone, strengthening
- AbbVie to Acquire Allerganhttps://modernaesthetics.com/news/abbvie-to-acquire-allergan/2471892/AbbVie Inc. and Allergan plc have entered into a definitive transaction agreement under which AbbVie will acquire Allergan i
- AAFPRS 2018 Stats: Rhinoplasty Reigns Supreme, Millennials Are The New Influencers, Plus Morehttps://modernaesthetics.com/news/aafprs-2018-stats-rhinoplasty-reigns-supreme-millennials-are-the-new-influencers-plus-more/2471961/Seventy-two percent of facial plastic surgeons saw an increase in cosmetic surgery or injectables in patients under age 30 in 2018, a significant increase from 2017, where over half of members noted this influx of younger patients, according to the latest statistics from the
- xMedica Launches Aesthetics Conference Focused on Energy Based Treatments for Male and Female Sexual Wellnesshttps://modernaesthetics.com/news/xmedica-launches-aesthetics-conference-focused-on-energy-based-treatments-for-male-and-female-sexual-wellness/2472007/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- BAAPS Calls for Brazilian Butt Lift Banhttps://modernaesthetics.com/news/baaps-calls-for-brazilian-butt-lift-ban/2472016/Due to the serious risks associated with the Brazilian butt lift, the British Association of Aesthetic Plastic Surgeons (BAAPS) is calling for a ban on the popular procedure until more data can be collected. The procedure is known to have the highest death rate of all cosmetic surger
- Allergan Shares Results of Higher Dose Botox Cosmetic for the Treatment Glabellar Lineshttps://modernaesthetics.com/news/allergan-share-results-of-higher-dose-botox-cosmetic-for-the-treatment-glabellar-lines/2472035/Allergan plc clinical study results of higher doses of Botox Cosmetic compared to Botox Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan conducted this trial to evaluate the duration of effect and safety of Botox
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://modernaesthetics.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2472047/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Bonti's Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgeryhttps://modernaesthetics.com/news/bontis-novel-neurotoxin-shows-promise-in-early-study-of-scar-reduction-after-mohs-surgery/2472052/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- First Patients Treated in Pulse Biosciences' Sebaceous Hyperplasia Studyhttps://modernaesthetics.com/news/first-patients-treated-in-pulse-biosciences-sebaceous-hyperplasia-study/2472061/Pulse Biosciences, Inc. says the first patients have been treated in its multi-center study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH). SH is an unsightly benign skin lesion that typically appears on facial skin an